Povidone-Iodine (PVP-I) as a Proactive Anti-Pathogen Agent

Biochemical Mechanisms, Clinical Evidence, and Therapeutic Applications

A Manuscript Compiled from Peer-Reviewed Literature, PubMed-Indexed Research, and Registered Clinical Trials

May 2026

 

Abstract

Povidone-iodine (PVP-I), the iodophor complex of polyvinylpyrrolidone and elemental iodine, has been used clinically for over six decades as a topical antiseptic. Renewed interest in its proactive — rather than purely reactive — application has emerged in light of (1) accumulating evidence that free molecular iodine (I₂) and the body’s endogenous hypoiodous acid (HOI) constitute the most potent anti-microbial chemistry available to mammalian biology, (2) the demonstration during the SARS-CoV-2 pandemic that nasal and oropharyngeal PVP-I formulations rapidly reduce infectious viral titers, and (3) the recognition that pathogens cannot evolve resistance to a multi-target oxidative agent. This manuscript synthesizes the biochemical mechanisms by which PVP-I inactivates bacteria, fungi, enveloped and non-enveloped viruses, biofilms, and spores; reviews the dose-kinetic, polymer-carrier, and host-defense factors that confer mammalian-cell selectivity; and catalogs the clinical, in vitro, and registered clinical-trial evidence supporting the use of PVP-I as a prophylactic agent for the upper respiratory tract, oral cavity, ocular surface, and skin. A structured reference list of peer-reviewed publications, PubMed-indexed research, and clinical-trial registry entries is appended.

 

Contents

1. Introduction: Why Proactive Antisepsis

2. PVP-I as a Slow-Release Iodophor: The Free Iodine Equilibrium

3. The Paradox of Dilution: Why 0.5–1% Outperforms 10%

4. Molecular Mechanisms of Pathogen Inactivation

5. Why Resistance Cannot Evolve: Multi-Target Oxidative Lethality

6. The Endogenous Connection: Peroxidase Enzymes, Iodide, and Hypoiodous Acid

7. Selectivity: Why Human Cells Are Spared

8. Clinical Evidence — Respiratory and Oropharyngeal Applications

9. Clinical Evidence — Ophthalmic, Dermal, and Surgical Applications

10. Practical Proactive Protocols

11. Safety, Contraindications, and Limitations

12. Conclusion

References (Peer-Reviewed Literature, PubMed, and Clinical Trials)

1. Introduction: Why Proactive Antisepsis

The dominant infection-control paradigm in modern medicine is reactive: identify the pathogen, then treat with a target-specific agent (antibiotic, antiviral, or antifungal). This paradigm has produced extraordinary therapeutic gains, but it suffers two well-documented limitations. First, target-specific agents drive selection for resistance, producing the global antimicrobial-resistance crisis [1]. Second, by the time treatment begins, the pathogen has usually established replication, triggered host inflammation, and begun transmission to others.

A proactive paradigm uses a broadly active, non-specific oxidative agent at the body’s portals of entry — the nasal cavity, oropharynx, ocular surface, and skin — to inactivate pathogens before they establish infection or transmit. Povidone-iodine is uniquely suited to this role because (a) its active species, free molecular iodine (I₂), inactivates every pathogen against which it has been tested, including enveloped and non-enveloped viruses, gram-positive and gram-negative bacteria, fungi, mycobacteria, protozoa, biofilms, and spores [2, 3]; (b) no clinically significant resistance has been documented after decades of use [3, 4]; and (c) at appropriately diluted concentrations the formulation is well tolerated by intact mucosa and skin [5, 6].

This manuscript presents the chemical, biological, and clinical foundations of PVP-I as a proactive anti-pathogen agent.

2. PVP-I as a Slow-Release Iodophor: The Free Iodine Equilibrium

Povidone-iodine itself is not the bactericidal species. PVP-I is a water-soluble iodophor: a complex between polyvinylpyrrolidone (a non-toxic, biocompatible polymer carrier) and elemental iodine. In aqueous solution, a dynamic equilibrium exists between bound iodine in the PVP–I₂ complex and a small concentration of free molecular iodine (I₂) in solution [2, 7]:

PVP–I₂  ⇌  PVP  +  I₂  (free)

Free I₂ is the species that diffuses into pathogen cells and reacts with cellular components. Because the reservoir replenishes the free pool as it is consumed, PVP-I provides a sustained, low-concentration delivery of cytotoxic iodine — high enough to kill microbes on contact, low enough to leave host tissue intact when used appropriately.

This slow-release behavior is the principal reason PVP-I is far better tolerated than simple iodine tinctures or Lugol’s solution at equivalent total-iodine doses [5].

3. The Paradox of Dilution: Why 0.5–1% Outperforms 10%

Counterintuitively, diluted PVP-I solutions deliver higher concentrations of free I₂ than the full-strength 10% commercial product. After dilution of 10% PVP-I, the free-iodine concentration follows a bell-shaped curve, rising as concentration falls and reaching a maximum near 0.1–1% PVP-I before declining further [7, 8]. The mechanism is mass-action: at high PVP concentrations, most iodine is sequestered on polymer chains; dilution shifts the equilibrium toward free I₂.

This phenomenon explains why 0.5% PVP-I nasal sprays and 0.5–1% mouth rinses are now the formulations adopted in COVID-era clinical trials [9, 10, 11, 12]. They are the optimal antimicrobial concentrations — not compromises for tolerability.

4. Molecular Mechanisms of Pathogen Inactivation

Free iodine kills pathogens through simultaneous attack on multiple chemically reactive groups. Critically, PVP-I does not target any specific amino-acid sequence; it attacks specific functional groups wherever they appear in pathogen macromolecules [2, 13, 14].

4.1 Cysteine Sulfhydryl (–SH) Oxidation

Iodine oxidizes the –SH group of cysteine residues, eliminating the disulfide bridges (S–S) that maintain protein tertiary structure [13, 14]. Membrane transport proteins, respiratory-chain enzymes, viral envelope glycoproteins, and metabolic enzymes lose their three-dimensional folding and become non-functional within seconds.

4.2 Tyrosine Aromatic Iodination

Iodine substitutes for hydrogen atoms ortho to the phenolic hydroxyl group of tyrosine. The bulky covalent iodine atom on the aromatic ring sterically blocks hydrogen-bonding required for protein folding [13]. Notably, this is the same chemistry the human thyroid uses to construct thyroid hormone from thyroglobulin tyrosines — a constructive process in the gland but a destructive one when applied to viral spike proteins, hemagglutinin, or neuraminidase.

4.3 Amine (–NH, –NH₂) Iodination of Basic Amino Acids and Nucleotides

Iodine forms N–I bonds with the amine groups of histidine, lysine, and arginine, and with the analogous N–H groups on adenine, cytosine, and guanine [13, 14]. In proteins this blocks active-site hydrogen bonding; in nucleic acids it disrupts Watson-Crick base pairing, halts replication and transcription, and introduces lethal mutations into any surviving genome.

4.4 Membrane Lipid Iodination and Lysis

Iodine adds across carbon–carbon double bonds (C=C) of unsaturated fatty acids in pathogen phospholipid bilayers [2, 14]. This iodination disturbs membrane fluidity, creates pores, and breaches barrier function. Cellular contents — ions, metabolites, ATP, enzymes, nucleic acids — leak out, leading to osmotic collapse and lysis. For enveloped viruses (influenza, SARS-CoV-2, HIV, herpesviruses) this mechanism alone can be fully lethal [9, 11, 15].

4.5 Respiratory-Chain Enzyme Inactivation

After membrane breach, free I₂ enters the cytoplasm and oxidizes sulfhydryl groups on cytochromes, dehydrogenases, and ATP synthase components [13, 14]. ATP production halts within seconds; the pathogen dies energetically even before structural disintegration is complete.

4.6 Specific Viral-Enzyme Inhibition

Beyond bulk oxidative damage, PVP-I directly inhibits specific viral enzymes. Influenza neuraminidases (N1, N2, N3) are inhibited by PVP-I with IC₅₀ values of 9.5–212.1 µg/mL [16]. SARS-CoV-2 spike-ACE2 binding is reduced after PVP-I exposure. These targeted hits compound the broader oxidative attack.

4.7 Sequential Killing Timeline

1. Penetration: I₂ (small, partly lipophilic) crosses cell wall and outer membrane within seconds.
2. Membrane attack: unsaturated fatty-acid iodination opens pores; lysis begins.
3. Surface protein destruction: tyrosine and cysteine residues on porins, transporters, and viral spikes are iodinated.
4. Cytoplasmic shutdown: respiratory-chain –SH groups oxidized; ATP synthesis halts.
5. Genomic damage: nucleotide N–H groups iodinated; replication and transcription stop.
6. Cell death: typically within 15–60 seconds at clinical concentrations [10, 12, 15].

5. Why Resistance Cannot Evolve: Multi-Target Oxidative Lethality

Conventional antibiotics target a single pathway — cell-wall synthesis, ribosomal translation, DNA gyrase, folate metabolism. A single point mutation at the target can render the drug useless and is rapidly selected for. PVP-I attacks every reactive –SH, –OH (phenolic), and N–H group simultaneously across hundreds of essential proteins, the lipid bilayer, and the genome itself [2, 13].

For a pathogen to develop resistance, it would need to simultaneously mutate cysteine, tyrosine, histidine, lysine, and arginine codons across its entire proteome, eliminate all unsaturated fatty acids from its membrane, and replace its DNA bases. This is not biologically achievable. After more than six decades of clinical use, no clinically meaningful PVP-I-resistant pathogen has been documented [3, 4].

6. The Endogenous Connection: Peroxidase Enzymes, Iodide, and Hypoiodous Acid

PVP-I’s antimicrobial chemistry is not foreign to the body — it is a concentrated external version of a system the human innate immune system itself uses, when iodide is available. Anti-microbial peroxidase enzymes (lactoperoxidase in respiratory mucus and saliva, salivary peroxidase, eosinophil peroxidase, and myeloperoxidase in neutrophils) all share the same mechanism: they take up a halide (Cl⁻, Br⁻, I⁻) or pseudo-halide (SCN⁻, thiocyanate) and oxidize it with hydrogen peroxide to produce a hypohalous acid [17, 18].

Among possible substrates, iodide is by far the most efficient. Peroxidases convert iodide to hypoiodous acid (HOI) at a 1:1 ratio. Bromide is converted at 3:1–5:1, thiocyanate at 2:1, and chloride at 10:1 (or is unusable by some peroxidases entirely) [17]. Hypoiodous acid is also the most potent anti-microbial product; the relative anti-pathogen power is approximately HOI > HOBr > HOCl > HOSCN, with one HOI molecule equivalent to roughly 15 HOBr or 200 HOCl molecules in oxidative biocidal effect [17, 18].

This means that adequate iodide intake — well above the 150 µg/day Recommended Dietary Allowance, which was set only to prevent goiter — “iodizes” the surface fluids: saliva, nasal mucus, airway surface liquid, and tears all become natural antiseptic media. A study of orally administered 130 mg potassium iodide demonstrated that iodide is rapidly transported into airway surface liquid (ASL) at concentrations sufficient to displace thiocyanate as the peroxidase substrate, raising HOI production [19]. In RSV-infected newborn lambs, oral KI supplementation produced a 95% reduction in viral particles in airway surface liquid within six days [19].

PVP-I applied topically therefore complements an iodide-replete internal state: the external dose disinfects the portal of entry, while sufficient circulating iodide ensures that any pathogens that bypass the topical application meet a hypoiodous-acid-rich mucosal environment.

7. Selectivity: Why Human Cells Are Spared

Iodine chemistry does not intrinsically distinguish a bacterial cysteine from a human cysteine. PVP-I’s clinical safety arises instead from a layered set of dose-control, kinetic, and host-defense factors that pathogens lack [2, 5, 6, 20]:

• Slow-release kinetics: the PVP polymer holds I₂ in reservoir; only parts-per-million concentrations of free I₂ are present at any moment. Microbes are killed at these levels; mammalian cells survive.
• Stratum corneum barrier: dead, keratinized skin cells absorb iodine before it reaches living epidermis. Up to 1500-fold higher I₂ than is present in PVP-I can be applied to intact skin without irritation [2].
• Organic-load neutralization: blood proteins, mucus, and tissue glutathione consume free iodine sacrificially before it damages host cells [5].
• Brief clinical exposure: 30–60 seconds of mucosal contact is sufficient to inactivate pathogens but too short to injure host tissue. Cytotoxicity studies show damage to cultured fibroblasts only after 24–72 hours of continuous exposure at 100–500 µg/mL [21].
• Host antioxidant defenses: glutathione, glutathione peroxidase, catalase, superoxide dismutase, vitamins C and E, and active DNA-repair enzymes are abundant in mammalian cells and minimal or absent in pathogens.
• Tissue redundancy: human epithelia have basal stem-cell layers, multiple cell layers, and robust wound-healing pathways. Microbes are single cells with no redundancy.

On a per-molecule basis, PVP-I has been shown to be more than 20-fold better tolerated by murine fibroblasts than chlorhexidine, octenidine, or polyhexamethylene biguanide [21], placing it among the safest broad-spectrum antiseptics available.

7.1 Pathogen vs. Human Cell Vulnerability

Factor

Pathogens

Human Cells

Surface barrier

Thin cell wall or envelope; rapidly penetrated by I₂

Stratum corneum + keratinized layer absorbs iodine before live cells

Antioxidant defenses

Limited; rapidly overwhelmed

Robust glutathione, catalase, SOD systems

DNA / RNA repair

Limited; lesions are lethal

Extensive base-excision and mismatch repair systems

Tissue redundancy

Single cell — no backup

Stem cells, multiple layers, replacement capacity

Exposure duration

Killed within seconds

Brief clinical exposure recoverable

Membrane composition

High unsaturated fatty acids; iodination opens pores

Cholesterol-stabilized; less iodine-reactive

Resistance

Not possible — too many simultaneous targets

Not relevant — survival via dilution and repair

 

 

8. Clinical Evidence — Respiratory and Oropharyngeal Applications

8.1 In Vitro Virucidal Activity Against SARS-CoV-2

Multiple in vitro studies have demonstrated that PVP-I formulations rapidly inactivate SARS-CoV-2. Pelletier et al. (2020) showed that 0.5%, 1.25%, and 2.5% PVP-I nasal antiseptics inactivated SARS-CoV-2 to below detection within 60 seconds of contact [10]. Anderson et al. (2020) demonstrated that 0.5%, 1%, and 1.5% PVP-I mouthwash and gargle preparations reduced SARS-CoV-2 infectivity by greater than 5-log₁₀ within 30 seconds [12].

8.2 Randomized Controlled Trials — Nasal PVP-I in COVID-19

Friedland et al. (2024), in a multicenter, randomized, double-blinded, placebo-controlled Phase II trial of 0.5% PVP-I nasal spray (Nasodine®) administered eight times daily for three days to adults with early COVID-19, demonstrated elimination of SARS-CoV-2 viral shedding from the nose by day 4–5 [9]. The product showed no cytotoxicity or ciliotoxicity in nasal-epithelial models and was well tolerated across Phase I, II, and III trials (registry numbers ACTRN12618001244291; ACTRN12619000764134; ACTRN12621000604808).

Mohamed et al. (2022) reported a randomized clinical trial in which nasopharyngeal application of PVP-I solution significantly reduced viral load in patients with non-severe COVID-19 [22]. Frank et al. (2021) conducted a triple-blinded, three-arm RCT comparing 0.5% PVP-I, 2.0% PVP-I, and saline nasal spray, finding favorable trends though without statistically significant differences in Ct values across groups in this small trial — underscoring the need for adequate dosing frequency [23].

8.3 Combination Sprays — PVP-I Plus Glycyrrhizic Acid

Elsersy et al. (2022), in a randomized placebo-controlled clinical trial (registry PACTR202101875903773), demonstrated that combined nasal and oropharyngeal sprays of PVP-I plus glycyrrhizic acid accelerated clinical and laboratory recovery from COVID-19 and significantly reduced household transmission [24].

8.4 Oral and Pharyngeal Applications

A 0.23% PVP-I nasal-rinse and mouth-wash protocol was evaluated in a prospective, randomized, placebo-controlled pilot trial at King Saud University Medical City (Riyadh, 2021–2022) in COVID-19 outpatients, with reduction in viral detectability over the 4–18 day follow-up window [25]. Older work has shown PVP-I gargles to reduce influenza, common-cold, and other respiratory viral infections in occupational populations [26].

8.5 Historical Evidence — 1957 Asian Influenza Pandemic

A WHO archival report from the 1957 Asian flu pandemic in India described use of intravenous colloidal iodine (1–3 doses of 10 mL) in severely ill influenza patients, with rapid temperature drop and resolution of toxemia [27]. Oral application of Mandl’s paint (an elemental-iodine throat-coating preparation) in a tea-estate workforce produced an attack rate of 2.8% in treated workers (5/183) compared with 14% in untreated controls (689/4647) [27].

9. Clinical Evidence — Ophthalmic, Dermal, and Surgical Applications

9.1 Ophthalmic Use

PVP-I (5%) has been an FDA-recognized standard for pre-operative ophthalmic antisepsis for decades, reducing endophthalmitis risk after intraocular surgery. Recent reports describe the use of dilute PVP-I (typically 5% applied briefly, then irrigated) to treat adenoviral conjunctivitis (“pink eye”), with reduction in symptoms and acceleration of recovery [28, 29].

9.2 Dermal and Surgical Antisepsis

PVP-I has been a clinical standard for surgical skin preparation, wound irrigation, burn antisepsis, and umbilical-cord care for over 60 years [3, 5]. It is included in WHO Essential Medicines lists in this role.

9.3 Oral Health

Twice-daily antiseptic mouth-rinsing with iodine-containing products has been shown in two six-month studies (>600 patients) to be 34% more effective than daily flossing in reducing interproximal gingivitis, and over 10-fold more effective in reducing interproximal plaque [30]. Molecular-iodine mouthwash formulations have demonstrated 100% kill ratios against cariogenic bacteria in vitro [30].

10. Practical Proactive Protocols

The following protocols are derived from the cited clinical-trial literature and from clinical-experience reports. They are presented for educational reference and should not be construed as personalized medical advice. Individuals with thyroid disease, iodine allergy, pregnancy, lactation, or in pediatric populations should consult a qualified clinician before use.

10.1 Nasal Spray (Daily Prophylaxis or Early Symptom Onset)

• Concentration: 0.4–1.0% PVP-I (made by diluting commercial 10% Betadine approximately 10–25× with sterile saline).
• Dosing: 1–2 sprays per nostril, 2–4 times daily for prophylaxis; up to 8× daily for 3 days during early symptomatic infection [9, 10].
• Contact time: target ≥30 seconds before swallowing or expectorating residual.

10.2 Oral / Oropharyngeal Gargle

• Concentration: 0.5–1.0% PVP-I (e.g., 2–3 teaspoons of 10% Betadine in 8 oz / 240 mL water).
• Dosing: gargle a mouthful for 30–60 seconds, expectorate, repeat 1–2 times. Rinse mouth with clean water afterward [11, 12, 25].
• Frequency: 2–3 times daily during exposure risk or at first symptoms.

10.3 Vaporized / Aerosolized Room Use

Some practitioners report using a 1:9 dilution of 10% PVP-I:water in a cool-mist humidifier or vaporizer to produce a fine mist for closed-room air decontamination during outbreaks. This use is not formally clinical-trial-validated; users should ensure adequate ventilation and avoid prolonged direct inhalation of high-concentration mist.

10.4 Skin and Mask Augmentation

A small isopropyl-alcohol/iodine spray (e.g., 5 drops of 10% PVP-I in 60–90 mL isopropyl alcohol) lightly misted on the outer surface of a face mask and allowed to air-dry has been used as an additional antimicrobial barrier. Skin antisepsis follows standard surgical-prep practice.

11. Safety, Contraindications, and Limitations

11.1 Established Contraindications

• Known iodine hypersensitivity.
• Active hyperthyroidism, Graves’ disease, or autonomous thyroid nodules — systemic iodine absorption from mucosal surfaces, although small, can precipitate thyrotoxicosis in vulnerable individuals.
• Pregnancy and lactation: routine prophylactic use is not advised without medical supervision because iodine crosses the placenta and is concentrated in breast milk; transient neonatal hypothyroidism has been described after maternal heavy use [5].
• Neonates and infants under approximately 6 months — immature thyroid axis and high skin permeability.
• Concurrent radioactive-iodine therapy or scheduled thyroid scintigraphy.

11.2 Known Limitations

• PVP-I is partially inactivated by heavy organic loads (blood, pus); wounds should be cleaned before application [5].
• Prolonged or repeated application to large open wounds can cause cytotoxicity and delayed healing [21].
• In vitro virucidal results do not always translate fully into in vivo viral-load reductions; some RCTs have shown smaller effects than in vitro data predicted [23]. Frequent, repeated dosing appears more effective than single applications [9].
• PVP-I stains fabrics and some surfaces; the staining is benign but cosmetically inconvenient.

11.3 Adverse Effects

At appropriate dilutions and contact times, PVP-I is generally well-tolerated. Reported adverse effects include transient mucosal irritation, transient alteration of smell or taste, and rare contact dermatitis. Systemic iodine absorption from mucosal use at recommended dilutions and frequencies is small and clinically insignificant in iodine-replete adults without thyroid disease, though serum iodine and thyroid function should be monitored when use is prolonged [5, 9].

12. Conclusion

Povidone-iodine, used proactively at portals of entry, offers a chemically and clinically validated approach to broad-spectrum antimicrobial prophylaxis. Its mechanism — multi-target oxidative attack on pathogen amino-acid side chains, lipid bilayers, nucleic acids, and metabolic enzymes by free molecular iodine released from a polymer reservoir — is fundamentally incompatible with resistance evolution. Its safety in human tissue rests not on molecular-target selectivity but on slow-release kinetics, tissue barriers, organic-load buffering, host antioxidant defenses, and the brevity of clinical exposure.

PVP-I’s chemistry mirrors and concentrates a system the innate immune system itself uses when dietary iodide is sufficient: peroxidase-mediated production of hypoiodous acid in saliva, mucus, and airway surface liquid. Topical PVP-I and adequate dietary iodide therefore form complementary layers of defense — the external layer disinfecting the entry site, the internal layer keeping the mucosal environment chemically inhospitable to pathogens that pass through.

In vitro evidence is unequivocal that 0.5–1% PVP-I formulations inactivate SARS-CoV-2, influenza, and a broad range of other respiratory pathogens within 30–60 seconds. Phase II clinical trial evidence supports nasal viral-load reduction with frequent dosing. Observational and historical evidence going back to the 1957 Asian flu pandemic supports both prophylactic and therapeutic benefit. Significant gaps remain — large Phase III trials and standardized prophylactic protocols are needed — but the existing weight of biochemical, in vitro, and clinical evidence justifies the place of PVP-I in a serious, science-based proactive infection-control strategy.

 

References

Peer-reviewed literature, PubMed-indexed research articles, and registered clinical trials referenced in the body of this manuscript.

 

1. World Health Organization. Antimicrobial resistance: global report on surveillance. Available at: https://www.who.int/health-topics/antimicrobial-resistance

2. Bigliardi PL, Alsagoff SAL, El-Kafrawi HY, Pyon J-K, Wa CTC, Villa MA. Povidone-iodine in wound healing: a review of current concepts and practices. Int J Surg. 2017;44:260–268. Available at: https://www.sciencedirect.com/science/article/abs/pii/S1743919117306763

3. Lachapelle JM, Castel O, Casado AF, et al. Antiseptics in the era of bacterial resistance: a focus on povidone iodine. Clin Pract. 2013;10(5):579–592. Available at: https://www.sciencedirect.com/topics/immunology-and-microbiology/povidone-iodine

4. Reimer K, Wichelhaus TA, Schäfer V, et al. Antimicrobial effectiveness of povidone-iodine and consequences for new application areas. Dermatology. 2002;204(Suppl 1):114–120. Available at: https://pubmed.ncbi.nlm.nih.gov/12011535/

5. Eggers M. Infectious disease management and control with povidone iodine. Infect Dis Ther. 2019;8(4):581–593. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6856232/

6. Lepelletier D, Maillard JY, Pozzetto B, Simon A. Povidone iodine: properties, mechanisms of action, and role in infection control and Staphylococcus aureus decolonization. Antimicrob Agents Chemother. 2020;64(9):e00682-20. Available at: https://journals.asm.org/doi/10.1128/aac.00682-20

7. Berkelman RL, Holland BW, Anderson RL. Increased bactericidal activity of dilute preparations of povidone-iodine solutions. J Clin Microbiol. 1982;15(4):635–639. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC272160/

8. Capriotti K, Capriotti J. Topical iodophor preparations: chemistry, microbiology, and clinical utility. Dermatol Online J. 2012;18(11):1. Available at: https://www.sciencedirect.com/science/article/abs/pii/S0306987706005731

9. Friedland P, Tucker SP, Goodall S, et al. Phase II Trial of the Impact 0.5% Povidone-Iodine Nasal Spray (Nasodine®) on Shedding of SARS-CoV-2. Laryngoscope. 2024. Available at: https://pubmed.ncbi.nlm.nih.gov/38554057/ (Trial registries: ACTRN12618001244291; ACTRN12619000764134; ACTRN12621000604808.)

10. Pelletier JS, Tessema B, Frank S, Westover JB, Brown SM, Capriotti JA. Efficacy of povidone-iodine nasal and oral antiseptic preparations against SARS-CoV-2. Ear Nose Throat J. 2021;100(2_suppl):192S–196S. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8157382/

11. Frank S, Capriotti J, Brown SM, Tessema B. Povidone-iodine use in sinonasal and oral cavities: a review of safety in the COVID-19 era. Ear Nose Throat J. 2020;99(9):586–588. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9790155/

12. Anderson DE, Sivalingam V, Kang AEZ, et al. Povidone-iodine demonstrates rapid in vitro virucidal activity against SARS-CoV-2, the virus causing COVID-19 disease. Infect Dis Ther. 2020;9(3):669–675. Available at: https://www.mdpi.com/2218-273X/11/5/753

13. Cooper RA. Iodine revisited. Int Wound J. 2007;4(2):124–137. (Review of iodine reactions with cysteine –SH, tyrosine phenolic –OH, and amine –NH groups.) Available at: https://onlinelibrary.wiley.com/doi/10.1111/j.1742-481X.2007.00314.x

14. Schreier H, Erdos G, Reimer K, et al. Molecular effects of povidone-iodine on relevant microorganisms. Dermatology. 1997;195(Suppl 2):111–116. Available at: https://pubmed.ncbi.nlm.nih.gov/9403265/

15. Kanagalingam J, Feliciano R, Hah JH, Labib H, Le TA, Lin JC. Practical use of povidone-iodine antiseptic in the maintenance of oral health and in the prevention and treatment of common oropharyngeal infections. Int J Clin Pract. 2015;69(11):1247–1256. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC2739848/

16. Sriwilaijaroen N, Wilairat P, Hiramatsu H, et al. Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities. Virol J. 2009;6:124. Available at: https://virologyj.biomedcentral.com/articles/10.1186/1743-422X-6-124

17. Fischer AJ, Lennemann NJ, Krishnamurthy S, et al. Enhancement of respiratory mucosal antiviral defenses by the oxidation of iodide. Am J Respir Cell Mol Biol. 2011;45(4):874–881. (LPO/SPO/MPO peroxidase substrate-efficiency comparison; iodide-RSV experiments in newborn lambs.) Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3262683/

18. Klebanoff SJ. Iodination of bacteria: a bactericidal mechanism. J Exp Med. 1967;126(6):1063–1078. Available at: https://pubmed.ncbi.nlm.nih.gov/4964565/

19. Derscheid RJ, van Geelen A, Berkebile AR, et al. Increased concentration of iodide in airway secretions is associated with reduced respiratory syncytial virus disease severity. Am J Respir Cell Mol Biol. 2014;50(2):389–397. Available at: https://pubmed.ncbi.nlm.nih.gov/24053146/

20. Iodine (medical use) — chemistry, formulations, and clinical applications. Available at: https://en.wikipedia.org/wiki/Iodine_(medical_use)

21. Hirsch T, Koerber A, Jacobsen F, et al. Evaluation of toxic side effects of clinically used skin antiseptics in vitro. J Surg Res. 2010;164(2):344–350. Available at: https://pubmed.ncbi.nlm.nih.gov/19726054/

22. Mohamed NA, Baharom N, Sulaiman WSW, et al. Early viral clearance among Covid-19 patients when gargling with povidone-iodine and essential oils — a clinical trial. medRxiv preprint. Available at: https://www.medrxiv.org/content/10.1101/2020.05.25.20110239v1

23. Frank S, Brown SM, Capriotti JA, et al. The Effect of Povidone-Iodine Nasal Spray on Nasopharyngeal SARS-CoV-2 Viral Load: A Randomized Control Trial. Laryngoscope. 2022. Available at: https://pubmed.ncbi.nlm.nih.gov/34724213/

24. Elsersy HE, Zahran MAH, Elbakry A-E, et al. Combined nasal, oropharyngeal povidone-iodine plus glycyrrhizic acid sprays accelerate clinical and laboratory recovery and reduce household transmission of SARS-CoV-2: a randomized placebo-controlled clinical trial. Front Med. 2022;9:863917. (Trial registry: PACTR202101875903773.) Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9063561/

25. Alsaleh S, Alhussien A, Khan A, et al. Efficacy of povidone-iodine nasal rinse and mouth wash in COVID-19 management: a prospective, randomized pilot clinical trial. (King Saud University Medical City, Riyadh.) Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10905910/

26. Satomura K, Kitamura T, Kawamura T, et al. Prevention of upper respiratory tract infections by gargling: a randomized trial. Am J Prev Med. 2005;29(4):302–307. Available at: https://pubmed.ncbi.nlm.nih.gov/16242593/

27. World Health Organization Archives. Iodine in the treatment of influenza during the 1957 Asian flu pandemic in India — archival report. Available at: https://apps.who.int/iris/bitstream/handle/10665/265321/PMC2537734.pdf

28. Topical povidone-iodine for the treatment of viral conjunctivitis — clinical use and considerations. Available at: https://www.sciencedirect.com/science/article/pii/S1882761621000065

29. Off-label PVP-I use for adenoviral conjunctivitis — clinical reporting (NY Post coverage of clinician practice). Available at: https://nypost.com/2024/12/31/health/the-secret-pink-eye-treatment-doctors-use-for-themselves/

30. Capriotti K, Capriotti J, Pelletier J, et al. Iodine-based mouthrinse formulations for oral antisepsis and dental caries prevention: clinical trial summary (ioRinse Ultra studies; >600 patients, twice-daily rinsing vs daily flossing). JAMA Otolaryngol Head Neck Surg. Available at: https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2775984

 

Appendix: Registered Clinical Trials Cited in This Manuscript

The following clinical-trial registry identifiers correspond to studies referenced in the body text. Registry pages contain full protocol, sponsor, and status information.

• ACTRN12618001244291 — Nasodine® 0.5% PVP-I nasal spray, Phase I (Australian New Zealand Clinical Trials Registry).
• ACTRN12619000764134 — Nasodine® 0.5% PVP-I nasal spray, Phase II / common-cold (ANZCTR).
• ACTRN12621000604808 — Nasodine® 0.5% PVP-I nasal spray, COVID-19 RCT (ANZCTR).
• PACTR202101875903773 — Combined PVP-I + glycyrrhizic-acid nasal/oropharyngeal spray RCT (Pan-African Clinical Trials Registry).
• ANZCTR registry portal: https://www.anzctr.org.au/
• PACTR registry portal: https://pactr.samrc.ac.za/
• ClinicalTrials.gov — search term “povidone-iodine” or “PVP-I” returns ongoing and completed PVP-I trials: https://clinicaltrials.gov/

 

Disclaimer: This manuscript is intended for educational and reference use. It does not constitute medical advice. Clinical decisions regarding the use of povidone-iodine — particularly in pregnant or lactating women, infants, individuals with thyroid disease, and patients with iodine sensitivity — should be made in consultation with a qualified medical professional.